MHRA-100049-PIP01-21-M02 (update)

Key Facts

Active Substance
Active Substance:
  • IBRUTINIB
Invented Name
  • Imbruvica
  • Imbruvica
  • Imbruvica
  • Imbruvica
  • Imbruvica
  • Imbruvica
  • Imbruvica
  • Imbruvica
  • Imbruvica
  • Imbruvica
  • Imbruvica
  • Imbruvica
  • Imbruvica
  • Imbruvica
  • Imbruvica
PIP Number MHRA-100049-PIP01-21-M02 (update)
Pharmaceutical form(s)
  • Film-coated tablet
  • Capsule, hard
Therapeutic area
Therapeutic area:
  • Oncology
Conditions / Indications
Conditions / Indications:
  • Treatment of mature B-cell neoplasm
Route(s) of administration
Route(s) of administration:
  • Oral use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
Yes
Compliance Check Decision Date
Compliance opinion date
30/03/2022
Compliance Check Procedure Number
Compliance procedure number
MHRA-100049-PIP01-21-M02-C

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):IBRUTINIB.pdf
Published Date 17/05/2022